Abstract Library

#1801 Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-O

Introduction: PRRT with radiolabelled SSTR agonists is highly effective and has become an integral part of NET treatment. Tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. DOTA-JR11 (OPS201) is a very promising next-generation SSTR2-selective antagonist.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Nicolas G, Baum R, Herrmann K, Lassmann M, Hicks R,

Keywords: PRRT, 177Lu, OPS201,

#941 Comparison of Radiolableled Somatostatin Analogues and (131) I-MIBG Treatment for the Management of Patients with Metastatic/Progressive Phaeochromocytomas and Paragangliomas

Introduction: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGGs) and pheochromocytomas (PCCs). To date, there is no study comparing (131)I-MIBG and peptide receptor radionuclide treatment (PRRT) in those patients.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Nastos K, Toumpanakis C, Cheung V, Navalkissoor S, Quigley A,

Keywords: paraganglioma, pheochromocytoma, (131)I-MIBG, PRRT,

#125 Ectopic hormone secreting phaeochromocytoma: A francophone observational study

Introduction: Ectopic hormone-secreting phaeochromocytomas are rare and only small reports of 1-2 cases exist in the literature. In the past, this condition has been linked with increased malignancy, familial syndromes and ACTH secretion.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Kirkby-Bott J

Authors: Kirkby-Bott J, Brunaud L, Mathonet M, Hamoir E, Kraimps J,

Keywords: phaeochromocytoma, ectopic hormone secretion, ACTH, calcitonin, VIP, Il-6, renin, aldosterone, cortisol, testosterone,

#124 Management and outcomes of malignant paragangliomas and phaeochromocytomas

Introduction: Chromaffin-cell tumors include phaeochromocytomas and paragangliomas, represent a rare group of neuroendocrine tumors and are located in adrenal medulla or extra-adrenal sites, respectively. Ten percent of phaeochromocytomas and 15-35% of paragangliomas are malignant.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: TOUMPANAKIS C

Authors: Warner B, Chilkunda D, Khan M, Buscombe J, Caplin M,

Keywords: paragangliomas, phaeochromocytomas, chromaffin-cell tumours,